Hepatitis B virus (HBV) DNA screening of blood donations in minipools with the COBAS AmpliScreen HBV test

Kleinman, Steve; Strong, Douglas M.; Tegtmeier, Gary; Holland, Paul V.; Gorlin, Jed B.; Cousins, C. R.; Chiacchierini, R. P.; Pietrelli, Larry

doi:10.1111/j.1537-2995.2005.00198.x

Cited by 97 publications

(122 citation statements)

References 22 publications

Supporting

Mentioning

118

Contrasting

Order By: Relevance

“…Therefore implementing a highly sensitive assay for HBV DNA screening in Lebanese blood donors, should be considered to avoid any false negative results. Previous studies have shown that various NAT commercial assays differ in their sensitivity (36)(37)(38), this could be associated with various factors such Hepat Mon. 2017; 17 (7):e14250.…”

Section: Discussionmentioning

confidence: 99%

Low Prevalence of Occult Hepatitis B Infection Among Blood Donors in Beirut, Lebanon: Reconsider the Deferral Strategy of Anti-HBc Positive Blood Donors

et al. 2017

View full text Add to dashboard Cite

Background: Hepatitis B virus (HBV) infection remains one of the major infectious threats to human health. Since the implementation of highly sensitive HBV nucleic acid testing, occult HBV infection (OBI) has been detected. Occult HBV infection is characterized by a positive HBV DNA test with undetectable HBsAg (Hepatits B surface antigen). The prevalence of OBI varies significantly between geographic areas, genotypes, and population depending on the sensitivity of the detection assays used.

show abstract

Section: Discussionmentioning

confidence: 99%

Low Prevalence of Occult Hepatitis B Infection Among Blood Donors in Beirut, Lebanon: Reconsider the Deferral Strategy of Anti-HBc Positive Blood Donors

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The prevalence of OHB among HBsAg-negative donors varies in different parts of the world, and as mentioned above, depends on the endemicity of HBsAg carriers as well as the method used to test the virus. Reports from subsets of donors from North America and Western Europe have ranged from as low as 0 % (presence of anti-HBc) (10,11) to as high as 2.8 % (isolated anti-HBc) (12,13). Similarly, studies from Asia (especially from highly endemic regions) have indicated prevalence rates of HBV-DNAHBV DNA detection among blood donors ranging from 0.…”

Section: Transfusion Settingsmentioning

confidence: 99%

Occult Hepatitis B (OBH) in Clinical Settings

et al. 2012

View full text Add to dashboard Cite

Occult HBV infection has received increasing attention in recent years. Although the impact of occult HB in patients has not been determined, it appears to accelerate the progression of liver fibrosis and cirrhosis, ultimately leading to HCC. Occult HBV infection is unexpectedly frequent, in particular in hepatitis C virus (HCV) and in human immunodeficiency virus (HIV) infected individuals. This phenomenon has also been reported in blood transfusion settings. Therefore, OBH has a great impact on public health issues regarding blood safety, HBV diagnosis, etc. Context:Occult hepatitis B (OHB), or persistent HBV DNA in patients who are hepatitis B surface antigen (HBsAg) negative, is a recently recognized entity. In an attempt to summarize the issues, this review presents an overview of the current proposed hypothesis on the clinical relevance and also updates the knowledge on the classification of OHB in different clinical settings. Evidence Acquisition: OHB could be found in different population and clinical backgrounds including: viral co-infections (with either human immunodeficiency or hepatitis C viruses), HBV chronic carriers, dialysis patients, transplantation settings and certain clinical situations (named in here: special clinical settings) with no apparent distinguishable clinical parameters. Results: The exact magnitude, pathogenesis, and clinical relevance of OHB are unclear. Even the possible role exerted by this cryptic infection on liver disease outcome, and hepatocellular carcinoma development remains unknown. Conclusions: monitoring of Individuals with positive anti-HBc, mass immunization programs and improvement in diagnostic tools seem to be important to control the probability of transmission of HBV through cryptic HBV infection.Published by Kowsar Corp, 2012. cc 3.0.

show abstract

“…to the values predicted by incidence/window model. A 24-sample minipool NAT for HBV showed a yield of 1 : 352.451 over routine serologic screening, thus of a similar magnitude as HIV and HCV yield observed [93]. The downside of HBV NAT was small yield and cost-effectiveness in low prevalence areas, especially with minipool NAT, as well as the lack of sensitivity of even ID NAT to detect extremely sparse HBV DNA particles involved in transmission by transfusion.…”

Section: Discussionmentioning

confidence: 63%

Residual Risk of Hepatitis-B-Infected Blood Donations: Estimation Methods and Perspectives

Kupek

2013

ISRN Infectious Diseases

View full text Add to dashboard Cite

Despite a considerable reduction of the risk of HBV-infected blood donation entering blood supply (residual risk) due to improved screening by HBV NAT in the developed countries, the bulk of the people with HBV living in the developing countries still needs to be screened by serologic tests such as HBsAg and anti-HBc. Many of these countries lack resources for implementing NAT and are likely to remain so in the next decade or longer, thus depending on the HBV residual risk monitoring based on serologic testing and corresponding estimation methods. This paper reviews main HBV residual risk findings worldwide and the methods based on serology used for their calculation with repeat donors, as well as their extension to the first-time donors. Two artificial datasets with high (4.36%) and low (0.48%) HBV prevalence were generated to test the performance of five methods: the original incidence/window-period model based solely on HBsAg, its modification by Soldan in 2003, the Müller-Breitkreutz model, the HBsAg yield model, and its extension to include anti-HBc seroconversions within a year. The last model was closest to the true values of residual risk and had smallest variation of the estimates in both high and low prevalence data. It may be used for residual risk evaluation in relatively small samples, such as regional blood banks data.

show abstract

Hepatitis B virus (HBV) DNA screening of blood donations in minipools with the COBAS AmpliScreen HBV test

Cited by 97 publications

References 22 publications

Low Prevalence of Occult Hepatitis B Infection Among Blood Donors in Beirut, Lebanon: Reconsider the Deferral Strategy of Anti-HBc Positive Blood Donors

Low Prevalence of Occult Hepatitis B Infection Among Blood Donors in Beirut, Lebanon: Reconsider the Deferral Strategy of Anti-HBc Positive Blood Donors

Occult Hepatitis B (OBH) in Clinical Settings

Residual Risk of Hepatitis-B-Infected Blood Donations: Estimation Methods and Perspectives

Contact Info

Product

Resources

About